文献速递泌尿男性生殖肿瘤

帕博利珠单抗联合仑伐替尼一线治疗晚期非透明细胞肾细胞癌(KEYNOTE-B61):单臂、多中心、2期试验

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2023-07-11

KEYNOTE-B61是一项在14个国家48个中心开展的单臂2期试验,评估帕博利珠单抗联合仑伐替尼一线治疗晚期非透明细胞肾细胞癌的活性与安全性。158例患者中确认客观缓解率为49%(95%CI 41-57),≥3级治疗相关不良事件发生率为51%,8例(5%)患者因不良事件死亡且研究者认为均与治疗无关。结果支持该联合方案作为此类患者的一线治疗选择。

要点

  • 确认客观缓解率为49%(95%CI 41-57),含9例(6%)完全缓解和69例(44%)部分缓解。
  • 3-4级治疗相关不良事件发生于81/158例(51%),最常见为高血压37例(23%)。
  • 8例(5%)患者因不良事件死亡,研究者认为均与治疗无关。

核心结论

  • 帕博利珠单抗联合仑伐替尼在既往未治疗的晚期非透明细胞肾细胞癌患者中具有持久的抗肿瘤活性,安全性特征与既往研究一致。
  • KEYNOTE-B61的结果支持帕博利珠单抗联合仑伐替尼作为此类患者的一线治疗选择。

研究设计与样本

  • KEYNOTE-B61为单臂、2期试验,在14个国家(澳大利亚、加拿大、法国、匈牙利、爱尔兰、意大利、波兰、韩国、俄罗斯、西班牙、土耳其、乌克兰、英国和美国)的48个中心(医院和癌症中心)开展。
  • 纳入年龄≥18岁、既往未治疗、IV期非透明细胞肾细胞癌、卡氏功能状态评分≥70%的成人患者。
  • 所有入组患者接受帕博利珠单抗400 mg静脉注射每6周一次最多18个周期(2年)联合仑伐替尼20 mg口服每日一次,直至疾病进展、不可接受毒性或退出;仑伐替尼可继续使用超过2年。
  • 主要终点为独立中心审查按调整的实体瘤疗效评价标准(版本1.1)评估的确认客观缓解比例。
  • 活性与安全性在至少接受一剂研究治疗的所有患者(按治疗人群)中分析;试验注册号ClinicalTrials.gov NCT04704219,已停止招募但仍在进行。

主要发现

  • 2021年2月23日至2022年1月21日筛查215例患者,158例入组并接受治疗。
  • 基线中位年龄60岁(IQR 52-69),158例中男性112例(71%)、女性46例(29%),白人128例(81%)、亚裔12例(8%)、黑人或非裔美国人3例(2%)、种族数据缺失15例(9%)。
  • 截至数据截止日(2022年11月7日),中位研究随访14.9个月(IQR 11.1-17.4)。
  • 158例中78例确认客观缓解(49%;95%CI 41-57),其中9例(6%)确认完全缓解、69例(44%)确认部分缓解。
  • 3-4级治疗相关不良事件发生于158例中81例(51%),最常见为高血压37例(23%)、蛋白尿7例(4%)、口腔炎6例(4%);严重治疗相关不良事件发生于31例(20%);8例(5%)患者因不良事件死亡,研究者认为均与治疗无关(分别为心力衰竭、腹膜炎、肺炎、脓毒症、脑血管意外、自杀、气胸和肺栓塞各1例)。

关键数值与推荐

  • 确认客观缓解率49%(95%CI 41-57),包括完全缓解6%(9/158)和部分缓解44%(69/158)。
  • 3-4级治疗相关不良事件发生率51%(81/158),最常见为高血压23%(37/158)、蛋白尿4%(7/158)、口腔炎4%(6/158)。
  • 严重治疗相关不良事件发生率20%(31/158)。
  • 因不良事件死亡5%(8/158),研究者认为均与治疗无关。

临床怎么用

  • 原文结论指出结果支持帕博利珠单抗联合仑伐替尼作为既往未治疗的晚期非透明细胞肾细胞癌患者的一线治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy-based combinations including pembrolizumab plus lenvatinib are the standard of care for patients with first-line clear-cell renal cell carcinoma, but these combinations are not well characterised in non-clear-cell renal cell carcinoma. We aimed to assess the activity and safety of pembrolizumab plus lenvatinib as a first-line treatment for patients with advanced non-clear-cell renal cell carcinoma. METHODS: KEYNOTE-B61 is a single-arm, phase 2 trial being conducted at 48 sites (hospitals and cancer centres) in 14 countries (Australia, Canada, France, Hungary, Ireland, Italy, Poland, South Korea, Russia, Spain, Türkiye, Ukraine, the UK, and the USA). Adult patients (aged ≥18 years) with previously untreated stage IV non-clear-cell renal cell carcinoma and a Karnofsky performance status of 70% or higher were eligible for enrolment. All enrolled patients received pembrolizumab 400 mg intravenously every 6 weeks for up to 18 cycles (2 years) plus lenvatinib 20 mg orally once daily or until disease progression, unacceptable toxicity, or withdrawal; lenvatinib could be continued beyond 2 years. The primary endpoint was the proportion of patients with a confirmed objective response as per adjusted Response Evaluation Criteria in Solid Tumours (version 1.1) assessed by independent central review. Activity and safety were analysed in all patients who received at least one dose of study treatment (the as-treated population). This trial is registered with ClinicalTrials.gov (NCT04704219) and is no longer recruiting participants but is ongoing. FINDINGS: Between Feb 23, 2021, and Jan 21, 2022, 215 patients were screened; 158 were enrolled and received treatment. Median age at baseline was 60 years (IQR 52-69), 112 (71%) of 158 patients were male, 46 (29%) were female, 128 (81%) were White, 12 (8%) were Asian, three (2%) were Black or African American, and 15 (9%) were missing data on race. As of data cutoff (Nov 7, 2022), median study follow-up was 14·9 months (IQR 11·1-17·4). 78 of 158 patients had a confirmed objective response (49%; 95% CI 41-57), including nine (6%) patients with a confirmed complete response and 69 (44%) with a confirmed partial response. Grade 3-4 treatment-related adverse events occurred in 81 (51%) of 158 patients, the most common of which were hypertension (37 [23%] of 158), proteinuria (seven [4%]), and stomatitis (six [4%]). Serious treatment-related adverse events occurred in 31 (20%) of 158 patients. Eight (5%) patients died due to adverse events, none of which was considered related to the treatment by the investigators (one each of cardiac failure, peritonitis, pneumonia, sepsis, cerebrovascular accident, suicide, pneumothorax, and pulmonary embolism). INTERPRETATION: Pembrolizumab plus lenvatinib has durable antitumour activity in patients with previously untreated advanced non-clear-cell renal cell carcinoma, with a safety profile consistent with that of previous studies. Results from KEYNOTE-B61 support the use of pembrolizumab plus lenvatinib as a first-line treatment option for these patients. FUNDING: Merck Sharp & Dohme (a subsidiary of Merck & Co, NJ, USA), and Eisai.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Albiges L, Gurney H, Atduev V, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023. PMID: 37451291. doi:10.1016/S1470-2045(23)00276-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。